Form D — Quince Therapeutics, Inc.

0000912282-26-000809 · filed Jun 11, 2026

Offering amounts describe securities offered; amounts sold are issuer-reported as of each filing. Amendments can repeat earlier amounts. We do not add these figures into a capital-raised total. Missing amounts are not zero. Data coverage and methodology · How to interpret the amounts.

Check this disclosure on SEC EDGAR · More Biotechnology filings

Offering

Industry: Biotechnology
Exemptions: 06b
Reported offering amount: $186,422,679
Reported amount sold: $114,720,542
Minimum investment: $0
Investors: 27
Sales commission: $7,861,000
Finders' fees: $0

Issuer

Name: Quince Therapeutics, Inc.
CIK: 1662774
Entity: Corporation
Jurisdiction: CALIFORNIA
Year incorporated: —
Address: 611 Gateway Blvd., Suite 273
South San Francisco, CA 94080
Phone: 415-910-5717

Related persons

May not be accurate — issuers self-report this list and the SEC does not verify it. Cross-check the original SEC EDGAR filing if accuracy matters.

Dirk Thye · Executive Officer

South San Francisco, CA Find on LinkedIn ↗
Brigette Roberts · Executive Officer

South San Francisco, CA Find on LinkedIn ↗
Charles Ryan · Executive Officer

South San Francisco, CA Find on LinkedIn ↗
Brendan Hannah · Executive Officer

South San Francisco, CA Find on LinkedIn ↗
David Lamond · Director

South San Francisco, CA Find on LinkedIn ↗
Christopher Senner · Director

South San Francisco, CA Find on LinkedIn ↗
June Bray · Director

South San Francisco, CA Find on LinkedIn ↗

Other filings from this issuer

View the original filing on SEC EDGAR ↗